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ABSTRACT 
Despite its vastly demonstrated clinical efficacy, zidovudine (AZT) exhibits several 
suboptimal pharmacokinetic properties. In particular, its short plasmatic half-life (t1/2~1 h) 
is related to its low bound fraction to whole plasmatic proteins and in particular to human 
serum albumin (HSA). The design of prodrugs constitutes a promising strategy to enhance 
AZT pharmacokinetic properties, including its affinity for HSA. Recently, we reported the 
synthesis and chemical stability evaluation of three novel prodrugs of AZT obtained by 
derivatization with dicarboxylic acids (1-3). In this work, we present the design, synthesis 
and evaluation of chemical and enzymatic stabilities of a novel series of double prodrugs of 
AZT obtained by derivatization of 1-3 with a methylated l-phenylalanine moiety (4-6). In 
addition, the plasmatic protein binding properties were studied both by experimental and 
theoretical techniques. Prodrugs 4-6 were found to be relatively stable at pH 7.4 (t1/2 
between 4.1 and 57.8 h), while also demonstrated adequate stabilities in human plasma at 
37 C (t1/2 between 1.0 and 2.1 h). Also, prodrugs 4-6 were able to regenerate AZT at a rate 
that depended on the length of the alkyl chain in 1-3. Additionally, 4-6 exhibited a 
significantly increased binding to plasmatic proteins (between 52.1 and 72.5 %) with 
respect to AZT (12%) and 1-3 (between 26-34%). It is noteworthy that the displacement 
experiments with HSA site I and II markers, demonstrated that 4-6 bound to a different site 
than that of AZT and 1-3. Molecular modeling studies (i.e. molecular docking and free 
energy of binding analysis) were applied to shed light at an atomistic level on the 
pharmacodynamic properties driving the interaction of 4-6 with HSA. Overall, the present 
work provides a state of the art contribution to the design and development of novel 
prodrugs of AZT with optimized pharmacokinetic properties. 
 
 
 
Keywords: Zidovudine, prodrugs, Human Serum Albumin, Protein Binding, Molecular 
Modeling. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
1. INTRODUCTION 
Nucleoside reverse transcriptase inhibitors (NRTIs) were the first family of drugs 
approved by the Food and Drug Administration (FDA) to treat human immunodeficiency 
virus type-1 (HIV-1) infection,[1] the etiological agent causing the acquired 
immunodeficiency syndrome (AIDS) in humans. Among NRTIs, zidovudine (AZT, Figure 
1.a) constitutes a key component of the highly active antiretroviral therapy (HAART) 
protocols currently used to treat AIDS.[1, 2]  Despite its vastly demonstrated clinical 
efficacy, AZT exhibits several suboptimal pharmacokinetic properties, feature that often 
limits it efficacy and safety. Oral absorption of AZT is rapid and can be considered as 
complete; however first-pass metabolism significatively reduces its bioavailability. In 
particular, AZT is actively metabolized in liver by conjugation on it 5´OH position with 
glucuronic acid,[3] with glucurosyltransferase (isoform UGT2B7) being responsible of this 
catalysis.[4] Also cytochrome P450 is able to catalyze the reduction of the azido moiety 
present in AZT, originating the inactive compound 3'-amino-3'- deoxythymidine. The 
elimination half life of AZT is 1.1 hours,[5] with about 29% of the drug being eliminated 
unchanged in the urine and about 45% being excreted as the glucuronide. Upon absorption, 
AZT is bound in relatively low fractions to plasmatic proteins (30-38% in whole plasma 
and ~12% to pure human serum albumin (HAS)).[6] It also exhibits a short elimination half 
life of around 1.1 hours. In overall, the above presented pharmacokinetic properties results 
in the necessity of administering relatively high doses of drug in order to reach and 
maintain effective antiviral concentrations in plasma. This situation frequently leads to the 
occurrence of severe toxic effects and a low adherence of the patients to the antiretroviral 
treatment.[5, 7] In this context, numerous studies have dealt with strategies aimed at the 
optimization of the pharmacokinetic properties of AZT as a way of increasing its efficacy 
and safety, w.ith particular emphasis being focused in enhancing its plasmatic protein 
binding properties. 
Figure 1 
HSA is the main protein present in plasma, and is responsible for binding and 
transporting neutral and acidic compounds throughout the body.[8] Binding to plasmatic 
proteins constitutes a phenomena that determines the free drug concentration within body 
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fluids, both intra and extravascular, and as such constitutes a feature that needs to be 
carefully examined when attempting to optimize the efficacy and safety of a drug.[9] 
Structurally, HSA is formed by a single polypeptide chain bearing three domains, with each 
one containing two subdomains (Figure 2.a). To date, four main binding sites within the 
HSA molecule have been described, of which sites I and II (Figure 2.a,c) bind most of the 
drugs currently used in pharmacotherapy.[8] Characterizing the site within HSA to which 
drugs bind is of particular relevance, since drug-drug interactions may occur as a 
consequence of competition between co-administered drugs.[10, 11] 
Figure 2 
 
Significant efforts have been made to overcome AZT suboptimal pharmacokinetic 
properties by applying different chemical strategies. In particular, the design of prodrugs 
constitutes a very useful approach towards the possibility of improving most of the 
pharmacokinetic properties of AZT;[12-16] it is especially focused on the possibility of 
increasing its bound fraction to HSA and to modulate its cytotoxicity. AZT requires several 
phosphorylation steps on it 5´OH position in order to gain bioactivity, process that is 
selectively catalized by cytosolic thymidine kinase enzymes.[17] In this way, the chemical 
modification on the 5´OH position of AZT (i.e. activation by phosphorylation and 
inactivation by glucuronidation), determines a delicate balance related to its therapeutic 
efficacy and safety (Scheme 1). Since, only the unbound fraction to plasmatic proteins is 
available for enzymatic modification of the 5´OH, enhancing the affinity for HSA may 
represent profound changes both in the pharmacodynamic and pharmacokinetic properties 
of AZT. 
Scheme 1 
 In this way many prodrugs have been prepared by derivatizing the 5´OH of AZT in 
order to obtain inactive compounds requiring a chemical and/or enzymatic hydrolytic step 
prior to exhibiting bioactivity.In line with these efforts, we have previously reported the 
obtention of prodrugs of AZT linking ester and amide moieties at the 5´OH position to 
obtain both “single” and “double” prodrugs.[14-16, 18-21] As an example, oxalic acid 
(AZT-Ox) was used as linker chain between AZT and different essential aminoacids (Fig 
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1.b). Although some of these prodrugs showed promising biological activities as measured 
in anti HIV in vitro assays,[19] they had a poor resistance to chemical and enzymatic 
hydrolysis, which was also accompanied by a limited bound fraction to HSA.[6, 22-25] 
Recently, we reported the synthesis and chemical stability evaluation of three novel 
prodrugs of AZT obtained by derivatization with different dicarboxylic acids (1-3, Figure 
1.c): succinic (1), glutaric (2) and adipic (3) acids.[18] These single prodrugs exhibited 
adequate chemical stabilities at different pH values (2 - 7.4).[18] 
In order to continue with the development of the above mentioned prodrugs, in the 
present work we report the design, synthesis and evaluation of the chemical and enzymatic 
stability of a novel series of AZT double prodrugs obtained by further derivatizing prodrugs 
1-3 with a methylated l-phenylalanine moiety (4-6, Figure 1.d). In addition, their HSA 
binding properties were exhaustively studied by combining experimental and theoretical 
techniques in light of further evaluation of their biopharmaceutical behavior. The 
phenylalanine moiety was selected among natural aminoacids as a model endogenous 
scaffold since it has been reported to interact with carrier proteins in different tissues within 
the organism, including some of those that are considered as HIV-1 reservoirs.[26, 27] In 
addition, the methylation of the aminoacid was carried out to obtain lipophilic species at all 
physiological pH values and confer adequate bioavailability. 
Overall, both experimental and theoretical methods were combined to obtain and study 
novel AZT prodrugs that exhibited adequate chemical and enzymatic stability profiles with 
a significantly increased protein bound fractions to human plasma proteins compared to the 
leader compound. Based on the presented results, it is possible to state that prodrugs 4-6 are 
very promising molecules that merit further development as part of preclinical studies in 
the search of efficient anti HIV agents. 
 
2. EXPERIMENTAL SECTION 
2.1. Chemicals and reagents 
All chemical reagents were obtained from commercial sources (Sigma-Aldrich). AZT 
was generously provided by Filaxis Laboratories (Buenos Aires, Argentina). Acetonitrile 
(ACN), dichloromethane (DCM), chloroform, dimethyl sulfoxide (DMSO), acetone and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
methanol were of analytical grade. Buffer solutions were prepared as follows: phosphate 
buffers (100 mM): (a) pH 2.0: 0.3 mL/mL H3PO4 (b) pH 7.4: (8.63 mg/mL Na2HPO4; 4.70 
mg/mL NaH2PO4) and (C) pH 10.0: (8.63 mg/mL Na2HPO4), and PBS buffer pH 7.4 (NaCl 
8.01 g/L, KCl 0.20 g/L, Na2HPO4 1.42 g/L,KH2PO4 0.27 g/L)  all of which were 
prepared using milli-Q water. For quantification of samples by means of HPLC, milli-Q 
water and HPLC grade methanol and ACN were used for the mobile phase and sample 
preparation. 
2.2. Synthetic protocols 
Compounds 1-3 and the l-phenylalanine methyl ester were prepared as previously 
reported.[18] Prodrugs 4-6 were synthesized by reacting 1 eq. of 1-3, 1.5 eq. of N´,N´-
dicyclohexylcarbodiimide (DCC), 1.5 eq. of ethyl cyanoglyoxylate-2-oxime (Oxyma Pure 
®
) and 1 eq. of N,N-diisopropylethylamine (DIPEA) dissolved in 10 mL of anhydrous 
chloroform. The reaction mixture was maintained under magnetic stirring for 15 minutes 
(min) in an ice bath after which, 2 eq. of l-phenylalanine methyl ester (Phen-O-met)  were 
added. The resulting suspension was kept at room temperature overnight and filtered and 
the resulting solution was extracted with a 2M HCl solution (3 x 10 mL). The organic phase 
was evaporated to dryness and the residue was redissolved in a buffer pH 2:acetone (80:20) 
mixture (20 mL). This solution was subjected to normal-phase flash chromatography using 
Silica gel 60 PF254 (Merck) and eluted with buffer pH2:acetone mixtures (80:20 x 50 mL; 
70:30 x 50 mL; 60:40 x 100mL). The final solvent fraction was collected and the acetone 
was evaporated under vacuum. The resulting aqueous solution was extracted with DCM (3 
x 10 mL). Then, the organic phase was dried over sodium sulfate, filtered and evaporated to 
dryness. The desired product was obtained as a white solid in good yields. The 
corresponding structures were confirmed by 
1
H and 
13
C NMR using a Bruker Avance II 
400 spectrometer and acetone-d6 (99.9%, Sigma) as solvent. In addition, 4-6 were 
characterized by high resolution mass spectrometry (HRMS) using a Bruker Daltonics 
micro TOF QII LC-MS equipped with an electrospray ionization (ESI) interphase 
configured in positive mode. 
3´-Azido-3´-deoxy-5´-O-succinyl-N-methoxyphenylalaninethymidine (4): This 
prodrug was obtained by condensing 3´-azido-3’-deoxy-5’-O-succinylthymidine acid (1) 
and l-phenylalanine methyl ester. The corresponding product was obtained in yields of 
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63%, mp: 144-145 °C.
 13
CNMR (400 MHz, acetone-d6, TMS): d (ppm) = 10.8 (C11´´ ), 
11.61 (C7), 14.98 (C12´´ ), 25.01 (C10´´), 29.60 (C 2´´), 29.80 (3´´), 36.51 (C 2´), 37.42 (C 
8´´), 51.06 (C 5´), 56.15 (C 9´´), 60.54 (C 6´´), 62.99 (C 3´), 81.63 (C4´), 84.32 (C 1´), 
110.36 (C 5), 135.69 (C 6), 150.33 (C 2), 163.27 (C 4), 170.98 (C 1´´), 171.920 (C 4´´), 
172.20 (C 7´´).
 1
H NMR (400 MHz, Acetone, TMS): d (ppm) = 0.75 (M, 6H, J = 7.5 Hz, 
11´´-12 ´´-H), 1.72 (M, 3H, J = 1.2 Hz, 7-H), 1.92 (M, 2H, J = 2.01 Hz, 10´´-H),  2.31 (M, 
1H, J = 12.3 Hz, 2b´-H), 2.42 (M, 1H, J= 13.9Hz, 2a´-H), 2.52 (M, 4H, J = 16.3  Hz, 2’’ y 
3´´-H), 3.54 (S, 3H, J = 18.4 Hz, 8´´-H), 3.94 (M, 1H, J = 3.88 Hz, 4´-H), 4.15 (DM, 1H, J 
= 3.6  Hz, 5b´-H), 4.31 (DM, 1H, J = 3.6 Hz, 5a´-H), 4.34 (M, 1H, J = 4.01 Hz, 9´´-H), 4.38 
(DM, 1H, J = 5.46 Hz, 3´-H), 6.10(T, 1H, J = 24.4 Hz, 1´-H), 7.41 (D, 1H, J = 1.168 Hz, 
6H). HRMS (ESI) m/z calculated for C24H28N6O8
 
Na [M+nNa]
+
: 551.1861, found 
551.1855. 
3´-Azido-3´-deoxy-5´-O-glutaryl-N-methoxyphenylalaninethymidine (5):  This 
prodrug was obtained by condensing 3´-azido-3´-deoxy-5´-O-glutarylthymidine acid (2) 
and l-phenylalanine methyl ester. The corresponding product was obtained in yields of 
65%, mp: 150-151°C. 
13
CNMR (400 MHz, acetone-d6, TMS): d (ppm) = 11.70 (C7), 20.62 
(C3´´), 32.68 (C4´´), 34.18 (C2´) 36.16 (C2´´), 37.41 (C 10´´), 51.35 (C 9´´), 53.51 (C 7´´), 
60.82 (C 3´), 63.21 (C5´), 81.49 (C4´), 84.64 (C 1´), 110.32 (C 5), 126.61 -128.28 (C 12´´-
17´´), 129.17 (C 9´´), 135.74 (C 6), 150.32 (C 2), 163.31 (C 4), 171.49 (C 1´´), 172.04 (C 
5´´), 172.42 (C 8´´). 
1
H NMR (400 MHz, Acetone, TMS): d (ppm) = 1.70 (D, 3H, J = 1.2 
Hz, 7-H), 2.11 (T, 2H, J = 14.7 Hz, 4´´-H), 2.24 (M, 1H, J = 17.16 Hz, 2´´H), 2.33 (M, 1H, 
J = 26.2 Hz, 3b´´-H), 2.41 (T, 1H, J =7.24 Hz, 2´-H), 2.44 (M, 1H, J = 27.8 Hz, 3a´´-H), 
2.83 (C, 1H, J = 22.4 Hz, 10b´´-H), 2.99 (C, 1H, J = 19.4 Hz, 10a´´-H), 3.51 (S, 3H, J = 
18.4 Hz, 9´´-H), 3.96 (C, 1H, J = 13.72 Hz, 4´-H), 4.17 (M, 1H, J = 15.88 Hz, 5b´-H), 4.27 
(M, 1H, J= 16.8, Hz, 5a´-H), 4.39 (M, 1H, J= 18.6 Hz, 3´-H), 4.58 (M, 1H, J =22.2 Hz, 7´´-
H), 6.11 (T, 1H,J =13.12 Hz, 1´-H), 7.12 (M, 5H, J = 31.7 Hz, 12´´-16´´-H), 7.36 (S, 1H, J 
= 1.16 Hz, 6-H). HRMS (ESI) m/z calculated for C25H30N6O8 Na [M+nNa]
+
: 565.2017, 
found 565.2023. 
3´-Azido-3´-deoxy-5´-O-adipyl-N-methoxyphenylalaninethymidine (6): This prodrug 
was obtained by condensing 3´-azido-3´-deoxy-5´-O- adipylthymidine acid (3) and l-
phenylalanine methyl ester: The corresponding product was obtained in yields of 61%, mp: 
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159–160 °C. 13CNMR (400 MHz, acetone-d6, TMS): d (ppm) = 11.67 (C7), 24.12 (C3´´), 
24.72 (C4´´),33.34 (C2´) 36.47 (C2´´-5´´), 37.44 (C 11´´), 51.29 (C 10´´), 53.49 (C 8´´), 
60.85 (C 3´), 63.22 (C5´), 81.49 (C4´), 84.69 (C 1´), 110.25 (C 5), 126.57-129.18 (C 12´´-
17´´), 135.74 (C 6), 150.29 (C 2), 163.27 (C 4), 171.76 (C 1´´), 172.02 (C 6´´), 172.42 (C 
9´´).
 1
H NMR (400 MHz, Acetone, TMS): d (ppm) = 1.44 (M, 4H, J = 36.8 Hz, 3´´-4´´-H), 
1.71 (M, 3H, J = 13.6 Hz, 7-H), 2.25 (M, 2H, J = 24.4 Hz, 2´-H), 2.39 (M, 4H, J = 88.5 Hz, 
2´´-5´´H), 2.83 (M, 1H, J =36.8 Hz, 11b´´-H), 2.99 (M, 1H, J =36.0 Hz, 11a´´-H), 3.52 (S, 
3H, J = 18.4 Hz, 10´´-H), 3.96 (M, 1H, J = 33.6 Hz, 4´-H), 4.18 (DM, 1H, J = 30.4 Hz, 5b´-
H), 4.26 (DM, 1H, J= 30.0, Hz, 5a´-H), 4.39 (M, 1H, J= 41.2 Hz, 3´-H), 4.58 (M, 1H, J 
=40.0 Hz, 8´´-H), 6.08 (T, 1H,J =36.0 Hz, 1´-H), 7.11 (M, 5H, J = 70.0 Hz, 13´´-17´´-H), 
7.37 (S, 1H, J = 13.6 Hz, 6-H). HRMS (ESI) m/z calculated for C26H32N6O8 Na
 
[M+nNa]
+
: 
579.2174 found 579.2161. 
2.3. High performance liquid chromatography (HPLC) analyses 
HPLC analyses were done using a Jasco chromatograph equipped with a quaternary 
pump and a Jasco Multiple Wavelength detector (Jasco UV- 2077 Plus) set at 270 nm. To 
perform chromatographic separations, a Phenomenex Synergy Fusion C18 analytical 
column (4.0 x 250 mm, 5 mm particle size) coupled to a Phenomenex Security Guard 
Fusion RP (4.0 x 30 mm) guard column was used. Chromatographic analyses were carried 
out using mobile phase gradients at a flow rate of 1 mL/min as follows: 0-2.5 mins: a 
mixture of a pH 2.0 phosphate buffer (0.1 mM): methanol (53:47, v/v), with a linear change 
between 2.5-9.5 mins to a 30:70 v/v composition. The mobile phase composition was kept 
constant from 9.5-12.0 mins. To ensure the re-equilibration of the mobile phase 
composition and the column conditions, the solvent gradient was reverted to initial 
conditions for 4.0 mins before the next injection was performed. The total run time for each 
injection was 15 min, with a sample injection volume of 10 μL. 
2.4. Sample preparation procedures 
Samples intended for HPLC analysis were prepared by means of a solid phase extraction 
(SPE) methodology using Strata-X Phenomenex SPE cartridges. The corresponding 
procedure involved five analytical steps: (a) cartridges were preconditioned by sequentially 
adding 2.0 mL of methanol followed by (b) an equilibration step with 2.0 mL of pH 2 (100 
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mM) phosphate buffer. Before loading the cartridge, 80 µL of a HCl 2M solution and 50 
µL of the corresponding internal standard IS solution (compound 2 (0.15 mg/mL) for the 
analysis of 4 and 6 and compound 1 (0.15 mg/mL for the analysis 5) were added to the 
sample, homogenized, and (c) applied to the preconditioned cartridge at a flow rate of 1 
drop/s and dried under vacuum for 1 min. Afterwards, the (d) elution of the analytes was 
performed using 1mL of HPLC grade ACN, which was then (e) evaporated to dryness 
under a N2 stream at 40 °C, and stored at -20 °C. On the day of analysis, the samples were 
redissolved in 200 µL of a phosphate a buffer pH 2: methanol (80:20) mixture and 
subjected to HPLC analysis as stated before. 
2.5. Chemical and enzymatic stability studies 
The chemical stability of 4-6 was studied at pH 2.0, 7.4 and 10.0 using the 
corresponding phosphate buffers. A stock solution (1.0 mg/mL) of each prodrug was 
prepared in DMSO, from which the corresponding working solutions (4.5 x10
-6
 M) were 
prepared by adding 60 µL of the stock solution to 25 mL of buffer. Ten aliquots (2 mL) 
were withdrawn from the working solution, placed into sealed vials and incubated in a 
water bath at 37 °C. Samples intended for analysis were collected at convenient time 
intervals for each compound and assay condition. 
For the enzymatic stability studies, stock solutions (10.0 mg/mL) of each prodrugs were 
prepared in DMSO. An aliquot (60 µL) of each stock solution was added to 2 mL of human 
plasma that was preincubated at 37 C to attain the final working concentration (5.5 x 10-4 
M). Aliquots of the spiked plasma (50 µL) were withdrawn at convenient time intervals and 
diluted with 2 mL of pH 2.0 phosphate buffer prior to being subjected to sample 
preparation and HPL  analysis. Fresh human plasma was generously supplied by the 
Instituto de Hematología, Hemoterapia y Banco de Sangre, Universidad Nacional de 
Córdoba, Argentina.  
2.6. Plasmatic protein binding assays 
Fresh human plasma was filtered over glass wool before use and the concentration of 
total proteins (TP) and HSA were determined using commercially available kits (Proti 2, 
Weiner lab®, Argentina, and  Albúmina, Weiner lab®, Argentina, for TP and HSA, 
respectively) according to the instructions provided by the manufacturer. All samples used 
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in the binding assays exhibited TP concentrations between 5.5–5.8 g/dL and HSA 
concentrations between 3.6–4.1 g/dL.  
To perform the binding assays, stock solutions (1 mg/mL) of 4-6 were diluted in pH 7.4 
PBS buffer to a concentration of 0.01 mg/mL. Aliquots (600 µL) of the resulting working 
solutions were incubated with 600 µL of human plasma at 37 °C under gentle stirring for 
10 min. The corresponding protein bound fraction was separated from the free fraction by 
ultrafiltration using a micropartition system (Centrifree®UF, Millipore, 1 mL) equipped 
with an Ultracel YM-T membrane (cut-off 30 KDa). Ultrafiltration devices were 
centrifuged at 2000 rpm for 5 min, collecting less than 25% of the initial volume in the 
ultrafiltrate in order to avoid displacements in the binding equilibrium between the drug 
and the corresponding protein.[6] The samples intended for analysis were prepared by 
mixing 100 µL of ultrafiltrate and 50 µL of the corresponding internal standard IS (AZT-
Glu (2) 0,015 mg/mL for 4 and 6; AZT-Suc (1) 0,015 mg/mL for 5). Binding assays were 
performed in quintuplicate. 
Three experimental conditions were assayed: a) pure human plasma only, b) human 
plasma spiked with salicylic acid (SAL), and c) human plasma spiked with diazepam 
(DZP). 
The results are expressed as percentage of bound fraction (Fb) and were calculated using 
eq. [1]: 
 
where CS corresponds to concentration quantified in the ultrafiltrate and CI to the analyte 
concentration in the incubated plasma. 
2.7. Molecular modeling studies 
The initial structures of the simulated ligands were constructed using MarvinSketch 
v.16.2.15 developed by ChemAxon Ltd.[28] With respect to the structure of HSA, three 
different crystallographic structures were used as receptor templates: a) HSA in complex 
with AZT and Myr (PDB code: 3B9L),[29] b) the crystallographic complex between SAL, 
Myr and HSA (PDB code: 2I30)[30] and c) the complex between DZP, Myr, and HSA, 
which was constructed by combining PDB code: 2BXF [8] and PDB code: 1E7G.[31] 
Fb = 100 – ((CS/CI) *100) eq. [1] 
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The complexes between the studied molecules and HSA were obtained by molecular 
docking simulations, which were performed using software packages developed by 
OpenEye Scientific Software.[32] The corresponding procedures consisted of three stages: 
a) ligand conformer library generation, which was performed by applying an energy 
threshold of 10 kcal/mol and using the OMEGA software,[33, 34] b) docking assays which 
were conducted by applying a fast rigid exhaustive docking approach as implemented in the 
FRED3 software [35, 36] and using the ChemGauss3 scoring function to evaluate and score 
the resulting docked poses. The final stage involved the c) docked pose extraction and 
visualization, which was performed using the VIDA v.4.3.0 software developed by 
OpenEye Scientific Software.[37] The lowest energy docked pose was selected for further 
analysis by means of free-energy of binding analysis. 
Based on the complexes with HSA predicted by molecular docking, the free energy of 
binding was calculated using the MMPBSA.py [38] as implemented in AMBER16.[39] 
The ff14SB and GAFF [40] force fields implemented in AMBER16 were used to 
parameterize HSA and the corresponding ligands, respectively. The energy of binding was 
estimated by taking into account the solvation energies of the interacting molecules, in 
addition to the molecular mechanics (MM) energies. The contribution of polar solvation 
energies was computed using the generalized Born (GB) implicit solvent model, while the 
non-polar contribution to the solvation energy was calculated based on the solvent 
accessible surface area (SASA).[41]. Intermolecular interactions were computed and 
depicted using the VMD v.1.9.3. and LigPlot+ v.1.4.5 software.[42, 43] 
 
3. RESULTS AND DISCUSSION 
3.1. Synthesis of prodrugs 4-6 
In a first step, prodrugs 1-3 were obtained following our previously reported 
procedure,[18] after which the synthesis of prodrugs 4-6 was conducted by condensing 1-3 
and a phenylalanine methyl ester aminoacid (Scheme 2). The procedure implemented was 
straightforward and resulted in the obtention of the desired compounds with acceptable 
yields. Although several synthetic procedures have been used for this kind of condensation 
procedures,[44, 45] the OxymaPure/DCC coupling strategy, widely used for the synthesis 
of peptides, resulted in a simple and efficient procedure.[46-48] Also, the method 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
developed is expected to be feasible for being scaled up under safer conditions compared to 
the use of explosive benzotriazole derivatives.[46] It is noteworthy that the developed 
methodology allows the exploration of a wider chemical space for the diacid linker chain 
compared to classic methodologies in which cyclic anhydrides are used.[49] The possibility 
to explore a wide chemical space for the linker chain constitutes a key feature for the design 
of this kind of prodrugs, since (as will be presented later in this work), the 
biopharmaceutical properties of the resulting compound is highly dependent on the linker 
chain structure. 
Scheme 2 
3.2. Chemical and plasmatic stability 
In order to assess the chemical and enzymatic stability of 4-6, as well as their ability to 
regenerate the lead drug AZT, both the rate of chemical (pH 2-10) and enzymatic (human 
plasma) hydrolysis were determined (Table 1). We observed that all the compounds 
exhibited a pseudo-first order hydrolysis kinetics, with the corresponding concentration vs. 
time profiles being determined (Fig. S1-S3, Suppl. Mat.). All compounds showed to be 
stable at pH 2 for 24 hs. In relation to pH 7.4 and 10, the hydrolysis constant (k) and half 
life time (t1/2) were calculated from the corresponding profiles and are shown in Table 1. 
Table 1 
From the chemical stability of the double prodrugs 4-6, we observed that unlike the 
single prodrugs (1-3), the former were able to regenerate AZT at pH 7.4. The calculated t1/2 
values were 4.1, 7.5, and 57.8 hs for 4, 5, and 6, respectively (Table 1). It is evident that the 
addition of the aminoacid scaffold to the single prodrug enhanced the reconversion of 4-6 
to AZT, with the rate of this reconversion being strongly dependent on the length of the 
chain included in 1-3. Under strongly alkaline conditions (pH 10), all the prodrugs 
exhibited a significantly higher hydrolysis rate, with all of them exhibiting t1/2 values of 10 
min or lower (Table 1). It is noteworthy that the unique chemical hydrolysis product 
originated from 4-6 corresponded to AZT, with no 1-3 being detected. This observation is 
consistent with the fact that amide moieties are more stable than esters. 
From assays in whole plasma, it was found that the single prodrugs 1-3 displayed a high 
resistance to enzymatic cleavage (Table 1), regenerating only very small amounts of AZT 
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throughout the 24 h sampling interval. Compounds 4-6, in contrast, were hydrolyzed at a 
rate strongly dependent on the structure of the compound and much faster than the single 
prodrugs 1-3. Figure S3.a-c presents the corresponding concentration vs. the time profiles 
determined for prodrugs 4-6, in which all the relevant species were quantified, i.e., AZT, 
the demethylated prodrug and the intact prodrug. As can be seen, in all cases the 
demethylated prodrug was generated by enzymatic hydrolysis, observing a rapid increase in 
its concentration and a second phase in which it was completely hydrolyzed. As expected, 
in all cases, the resulting final product was AZT. The enzymatic stability followed a similar 
trend to that of the chemical stability, with t1/2 values of 1.0, 1.5 and 2.1 hs for 4, 5, and 6 
respectively (Table 1, Fig. 3). In agreement with the chemical hydrolysis studies, the single 
prodrugs 1-3 were not detected during the assay, indicating that the plasmatic enzymes 
were not able to efficiently hydrolyzed the amide bond present in 4-6. 
 
Figure 3 
3.3. Binding of 1-6 to plasmatic proteins: experimental studies 
The bound fractions to whole plasma proteins was determined for 1-6 and compared to 
that of AZT (Table 2). Taking into account that HSA is the main plasmatic protein, two 
well-known HSA binding site displacers were used in order to identify the binding site for 
each prodrug: salicylic acid (SAL, site I marker) and diazepam (DZP, site II marker).[6, 50, 
51] 
In agreement with our previous studies,[6, 23] AZT exhibited a low bound fraction to 
plasmatic proteins (13.8±1.4 %). Conversely, the single prodrugs 1-3 displayed a moderate 
increase in their bound fractions (33.2, 26.8 and 34.1 for 1, 2, and 3, respectively). Note 
that 1-3 exhibited a considerably higher bound fraction compared to AZT-Ox 
(10.4±1.8%),[6] as determined in a previous report. Clearly, the increase in the chain length 
of 1-3 separating the AZT scaffold and the ionized carboxylate moiety allowed a more 
efficient binding mode to HSA. From the displacement assays, we observed that SAL (site 
I marker) was able to efficiently displace the bound fractions of 1-3 (8.1, 1.8, and 4.8 % for 
1, 2, and 3, respectively), evidencing the fact that they were bound to site I of HSA. These 
results are in agreement with the binding of AZT-Ox,  as was previously reported.[6] 
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When the double prodrugs 4-6 were studied, considerably higher bound fractions with 
respect to AZT were found (52.1, 59.7 and 72.5 % for 4, 5, and 6, respectively). From the 
displacement studies with SAL, we observed no reduction in the bound fractions, indicating 
that 4-6 were not bound to site I in HSA. In contrast, when the displacement was studied 
using DZP (site II marker), a reduction in the bound fraction was quantified, indicating that 
4-6 were bound with a high affinity to site II. Consequently, we obtained both a higher 
affinity for HSA and a change in the site of binding by designing these double prodrugs. 
 
Table 2 
 
3.4. Binding of 1-6 to plasmatic proteins: theoretical studies 
To study the mode of binding of 1-6 to HSA at an atomistic level, molecular modeling 
techniques (i.e. molecular docking and free-energy of interaction analysis) were performed. 
To accomplish these studies, the crystallographic structure of HSA complexed with AZT 
and Myr (PDB code: 3B9L) was used as structural template,[29] while the complex HSA 
with salicylic acid and Myr (PDB code: 2I30) was used to model displacement assays.[30] 
Compounds 1-3 were docked to site I of HSA, observing that in all cases the lowest 
energy bound mode was characterized by the establishment of intermolecular interactions 
with the residues Tyr150, Ser192, Lys195, Gln196, Lys199, Val241, Cys245, Arg257, 
Ser287, His288 and Ala291 (Fig 4.a-c, Fig. S15). This binding mode is homologous to that 
observed for AZT in X-ray studies.[29] Also, from the per-residue free energy of 
interaction analysis (Table 3) it can be observed that 1-3 established strong electrostatic 
interactions with Arg257 (-8.62, -13.23 and -14.04 Kcal/mol, respectively), leading to an 
enhanced affinity for HSA compared to AZT, which is not able to establish stabilizing 
interactions with this residue (1.15 Kcal/mol). The electrostatic interactions with Arg257 is 
crucial to the binding of acidic drugs to HSA, such as SAL (-13.45 Kcal/mol), which is also 
consistent with the displacement of 1-3 elicited by this site I marker. In addition, prodrugs 1 
and 2 were able to establish interactions with His288 (-5.66 and -1.49 Kcal/mol, 
respectively), which was not observed for SAL. The interaction with His288 is possible 
because the negatively charged carboxylic acid is oriented towards the vicinity of His288 
by the linker chain spacer of two and three carbon atoms present in 1 and 2, respectively.  It 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
is noteworthy that the ΔGsum values presented in Table 3 are in agreement with the bound 
fractions determined experimentally (Table 2), with higher interaction energies calculated 
for 1 and 3 compared to 2. Also, the overall interaction energies calculated for 1, 2 and 3 (-
20.75, -18.10 and -20.28 Kcal/mol, respectively) are significantly higher than those 
calculated for AZT (-2.72 Kcal/mol). This observation is consistent with their enhanced 
affinity for plasmatic proteins observed experimentally. 
Figure 4 
Table 3 
The binding of prodrugs 4-6 was modeled to HSA site II based on the results obtained in 
the displacement assays. To construct the receptor template, the structure corresponding to 
the crystallographic complex between HSA and DZP (PDB code: 2BXF)[8] was 
superimposed on the crystal structure of HSA with Myr (PDB code: 1E7G), after which the 
site II marker was pasted on the latter to generate the working receptor. 
The binding to site II was modeled using DZP as reference (Fig. 5.a). When prodrugs 4-
6 were docked in site II, it was found that the phenylalanine moiety was deeply buried 
within the site cavity (Figs. 5b-d, Fig. S16), while the AZT scaffold was oriented towards 
either the polar patch near the cavity entrance (Arg410, Tyr411 and Ser489) or towards the 
solvent exposed region lying outside the binding cavity (prodrug 6). Table 4 presents the 
per-residue MMGBSA binding free energy analysis for the binding of DZP and 4-6 to site 
II. As can be seen DZP shares several interaction spots with 4-6 (Glu383, Pro384, Leu387, 
Ile388, Asn391, Phe403, Leu407, Leu430, Gly434, Ala449, Glu450 and Leu453), which is 
consistent with the displacements observed experimentally. As can be observed, the 
binding of 4-6 is mostly stabilized by hydrophobic contacts, with extensive interactions 
being established with Ser342, Glu382, Pro486, Phe488, Ala490 and Leu491 (Table 4). It 
is evident that these relatively bulky and hydrophobic prodrugs are able to occupy an 
extensive buried area within site II. Also, the sum of interaction energies (ΔGsum) calculated 
for 4-6 (-13.22, -14.13 and -19.26 Kcal/mol, respectively) are in agreement with the bound 
fractions observed experimentally, with the higher interaction energies and bound fractions 
being observed for prodrug 6 (72.8%). It is noteworthy that higher interaction energies 
were calculated for 4-6 compared to DZP, which is consistent with the limited capacity of 
the latter to displace the prodrugs bound to site II (Table 2). 
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Figure 5 
Table 4 
As mentioned above the chemical modification of prodrugs 4-6 produced a change in the 
HSA binding site selectivity with respect to AZT and prodrugs 1-3. To further study the 
molecular basis behind this behavior, the binding of 4-6 to site I was simulated and the 
corresponding interaction energies were calculated (Table 5). As can be seen, unfavorable 
binding interactions with residues lying within site I were found (ΔGsum:  3.88, 3.43, and 
2.51 Kcal/mol for 4, 5, and 6, respectively). In this case, the positively charged residues 
His288 and Arg257 did not establish stabilizing interactions, which is in agreement with 
the experimental findings that showed no affinity of 4-6 for this site. Thus, the presented 
methodology may also be useful to predict the binding site of this family of prodrugs to 
HSA. 
Table 5 
4. CONCLUSIONS 
In this work, novel double prodrugs of AZT (4-6) were obtained by derivatization of 
single AZT prodrugs 1-3 with a methylated phenylalanine moiety. The reported synthetic 
protocol and associated purification procedures are simple and efficient, and as such are 
feasible to scale up the production of these kinds of prodrugs, if necessary. Also, key 
biopharmaceutical properties were profiled in view of further evaluating the performance 
and benefits of 4-6, including their chemical and enzymatic stability and their 
corresponding plasma protein binding capabilities compared with the lead drug AZT. We 
found that the design and synthesis of prodrugs 4-6 resulted in compounds with improved 
biopharmaceutical properties (i.e. chemical and enzymatic stability and binding to  
plasmatic proteins) compared to the lead molecule AZT. Noteworthy, all of studied 
prodrugs were able to regenerate the lead molecule at an efficient rate under physiological 
conditions (pH 7.4 and human plasma). This observation represents a significant 
improvement in comparison with the single prodrugs 1-3, which exhibited a high stability 
under the above mentioned conditions and were unable to regenerate AZT at therapeutic 
compatible rates. 
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Regarding the plasmatic protein binding, all the prodrugs (i.e. single and double) showed 
increased bound fractions compared with AZT, with 4-6 exhibiting the highest bound 
fractions. Remarkably, the single prodrugs 1-3 were bound to site I of HSA, while the 
double prodrugs 4-6 were bound to site II. Molecular modeling techniques were able to 
exhaustively describe at an atomic resolution the structural basis behind this behavior. 
Overall, the described protein binding properties represent potential, significant benefits for 
the novel developed prodrugs (4-6), since upon bioactivation and AZT regeneration in body 
fluids, no competition is expected for HSA binding, which leads to an improved 
biopharmaceutical profile of the parent drug. In addition to the enhanced biopharmaceutical 
properties, prodrugs 4-6 are expected to exhibit lower side effect than the lead compound 
AZT, since phosphorylation on the 5´OH position is blocked for the prodrugs.  
The development of this family of prodrugs containing succinic, glutaric and adipic acid 
linked to a methylated phenylalanine moiety on the 5´OH position of AZT, resulted in a 
marked enhancement in their chemical and enzymatic stability properties and plasmatic 
protein binding capabilities compared to the prodrugs containing an oxalic acid linker that 
were reported previously by our group.[6, 23, 52] 
In conclusion, the present work is a valuable effort to design and development of novel 
double prodrugs of AZT with optimized pharmacokinetic properties. Also, the potential of 
applying molecular modeling techniques to screen prospective plasmatic protein binding 
properties has been demonstrated. In particular, it has been shown that it is possible to 
further study a large set of modified essential aminoacids as scaffolds for the design and 
obtention of new prodrugs. Based on the reported findings, in a future work will be 
continued to evaluate additional aminoacids as chemical moieties for the design of safe and 
more efficient AZT prodrugs. 
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Table 1. Chemical stability (pH 7.4 and 10.0) and plasmatic stability parameters for 
prodrugs 1-6 at 37°C. 
Prodru
g 
Chemical Stability Enzymatic Stability 
pH 7.4 pH 10 
k (min
-1
) t1/2 (min) k (min
-1
) t1/2 (min) k 
(min
-
1
) 
t1/2 (min) 
1 Stable* Stable* 0.001±0.001
*
 
630.1±2.1
*
 
0.000
1 ± 
0.000
1 
8022.5±555.
8 
2 Stable* Stable* 0.001±0.002
*
 
462.1±5.3
*
 
0.000
5 ± 
0.000
1 
1501.8±199.
9 
3 Stable* Stable* 0.002±0.001
*
 
385.1±2.6
*
 
0.000
3 ± 
0.000
1 
2695.6±666.
9 
4 0.003±0.00
1 
244.7±4.9 0.302±0.007 2.3 ± 0.7  0.011
0 ± 
0.000
5 
61.6 ± 2.2 
5 0.001±0.00
1 
452.5±16.7 0.077±0.003 7.9 ± 0.3 0.007
9 ± 
0.003
0 
88.2 ± 3.4 
6 0.002±0.00
1 
3465.7±48.
8 
0.070±0.002 10.4 ± 0.2 0.005
3 ± 
0.000
5 
125.1± 10.9 
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* Reported in our previous work.
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Table 2. Binding percentage of 1-6 to plasmatic proteins as measured in human plasma 
(HP) and human plasma containing site I (salicylic acid, SA) and site II (diazepam, DZP) 
markers. 
 Bound fraction (%) 
 HP HP + SAL HP + DZP 
AZT 13.8 ± 1.4 2.8±1.5 nd 
1 33.2 ± 6.8 8.1 ± 2.6 nd 
2 26.8 ± 0.5 1.8 ± 1.3 nd 
3 34.1 ± 1.5 4.8 ± 1.5 nd 
4 52.1  ± 5.3 51.2 ± 3.2 37.8 ± 1.4 
5 59.7 ± 4.3 61.5 ±2.5 50.6 ± 5.9 
6 72.5 ± 4.3 72.8 ± 3.2 48.8 ± 4.6 
HP: human plasma. SA: salicylic acid. DZP: diazepam. 
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Table 3. Per-residue MMGBSA binding free energy decomposition analysis (Kcal/mol) of 
compounds 1-3 and SAL in Site I. 
Contact AZT 1 2 3 SAL 
Tyr150 -1.35 -1.81 -1.10 -0.87 - 
Ser192 -0.14 -0.22 -0.50 -0.65 - 
Lys195 -1.17 -0.86 2.45 0.85 - 
Gln196 0.51 -1.23 -1.04 -1.79 - 
Lys199 -0.13 -0.85 -0.60 -0.87 - 
Leu219 - - - - -0.40 
Phe223 - - - - -0.21 
Leu238 - - - - -1.27 
Val241 -0.50 -0.70 -0.69 -0.76 -1.07 
Cys245 -0.61 -0.07 -0.32 -0.51 - 
Arg257 1.15 -8.62 -13.23 -14.04 -13.45 
Leu260 - - - - -1.78 
Ile264 - - - - -0.22 
Ser287 -0.14 -0.41 -0.51 -0.20 -2.18 
His288 -0.10 -5.33 -1.49 -0.12 - 
Ile290 - - - - -1.81 
Ala291 -0.24 -0.65 -1.16 -1.32 -1.76 
ΔGsum
a
 -2.72 -20.75 -18.10 -20.28 -24.15 
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Table 4. Per-residue MMGBSA binding free energy decomposition analysis (Kcal/mol) of 
compounds 4-6 and DZP in Site II. 
Contact DZP 4 5 6 
Ser342 - -1.14 -1.10 - 
Glu382 - -0.18 -0.12 -0.72 
Glu383 -0.35 -1.80 -1.16 -4.11 
Pro384 -0.69 -0.51 -1.04 -0.82 
Leu387 -2.16 -1.89 -1.11 -3.84 
Ile388 -2.93 -2.10 -1.61 -2.46 
Asn391 -0.87 0.96 0.68 -0.34 
Phe403 -0.44 -0.53 -0.76 -0.25 
Leu407 -0.60 -0.56 -1.06 -0.19 
Tyr411 -0.10 - - - 
Leu430 -0.68 -0.64 -1.73 -1.08 
Gly434 -0.37 -0.46 -0.83 -0.54 
Ala449 -0.81 -0.33 -0.14 -0.41 
Glu450 -0.54 -1.60 -1.44 -0.40 
Leu453 -1.12 -1.41 -1.79 -1.35 
Arg485 -0.62 - - - 
Pro486 - -0.10 -0.10 -0.59 
Phe488 - -0.71 -0.72 -0.18 
Ala490 - - - -1.35 
Leu491 - -0.25 -0.10 -0.63 
ΔGsum
a
 -12.26 -13.22 -14.13 -19.26 
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Table 5. Per-residue MMGBSA binding free energy decomposition analysis (kcal/mol) of 
compounds 4-6 in Site I. 
 
Residues 4 5 6 
Tyr150 -1.97 -3.60 -2.21 
Ser192 -0.71 -1.17 -0.78 
Lys195 1.97 1.26 0.93 
Gln196 -0.74 0.61 -1.15 
Lys199 3.29 1.16 3.53 
Val241 -0.21 0.17 -0.28 
Cys245 -0.39 -0.62 -0.85 
Arg257 4.65 7.19 5.02 
Ser287 -0.54 -0.54 -0.62 
His288 -0.16 0.13 -0.66 
Ala291 -1.32 -1.15 -0.43 
ΔGsum
a
 3.88 3.43 2.51 
a
 Total sum of all the residue interactions. 
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Figure Captions 
 
Figure 1. Molecular structures of: a) AZT, b) AZT prodrugs with oxalic acid (AZT-Ox) 
and aminoacids (AZT-Ox-AA), c) AZT prodrugs with dicarboxylic acids (1-3) and d) AZT 
double prodrugs (4-6) by derivatization of 1-3 with a methylated l-phenylalanine moiety. 
 
Figure 2. a) Three-dimensional structure of HSA showing the different domains and 
subdomains. b) Stereoview of Site I including warfarin as ligand, and c) Stereoview of Site 
II including diazepam as ligand.  
 
Figure 3. Concentration vs time profile of prodrugs 4, 5, and 6 in human plasma. 
Figure 4. Interaction pattern of compounds 1 (a), 2 (b), 3 (c) and SAL (d) in site I of HSA. 
 
Figure 5. Interaction pattern of DZP (a), 4 (b), 5 (c) and 6 (d) in site II of HSA. 
 
Scheme 1. Activation (triphosphorylation) and inactivation (glucuronidation) pathways 
described for AZT  
Scheme 2. Synthetic procedure for the obtention of prodrugs 4-6. 
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